Payment overview · 2025
General Payments
$1,194.72
35 reported records · 15 companies
Healthcare provider profile · identity verified
Scott Picou, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAMMOND, LA · NPI 1346506821
Verified facts
What the public records show
CMS Open Payments records show Scott Picou, MD received $1,194.72 in general payments during 2025 across 35 reported records.
Janssen Pharmaceuticals, Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Rexulti, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 527 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $259.47 | 21.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.26 | 20.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $146.86 | 12.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.67 | 11.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $103.15 | 8.6% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.83 | 3.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.40 | 3.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.74 | 3.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.51 | 3.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.80 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.25 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 1.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $18.24 | 1.5% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.33 | 1.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,194.72 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $259.47 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $225.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $146.86 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $120.57 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.44 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $103.15 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.74 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 527 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 209 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
209 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
89 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
527 | 68 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1069 | 192 |
| Pantoprazole Sodium | Pantoprazole Sodium | 850 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 773 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 682 | 103 |
| Lisinopril | Lisinopril | 573 | 113 |
| Furosemide | Furosemide | 539 | 107 |
| Eliquis | Apixaban | 527 | 68 |
| Gabapentin | Gabapentin | 516 | 80 |
| Potassium Chloride | Potassium Chloride | 418 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 70 |
| Trazodone Hcl | Trazodone Hcl | 384 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 75 |
| Metformin Hcl | Metformin Hcl | 333 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 326 | 72 |
| Memantine Hcl | Memantine Hcl | 305 | 30 |
| Losartan Potassium | Losartan Potassium | 291 | 54 |
| Omeprazole | Omeprazole | 285 | 54 |
| Meloxicam | Meloxicam | 281 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 278 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 278 | 35 |
| Donepezil Hcl | Donepezil Hcl | 263 | 26 |
| Alprazolam | Alprazolam | 236 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 48 |
| Famotidine | Famotidine | 230 | 43 |
| Januvia | Sitagliptin Phosphate | 223 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 54 |
| Farxiga | Dapagliflozin Propanediol | 209 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 191 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 21 |
| Sertraline Hcl | Sertraline Hcl | 184 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 162 | 24 |
| Jardiance | Empagliflozin | 162 | 21 |
| Mirtazapine | Mirtazapine | 156 | 20 |
| Alendronate Sodium | Alendronate Sodium | 152 | 33 |
| Allopurinol | Allopurinol | 151 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 43 |
| Ezetimibe | Ezetimibe | 149 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 27 |
| Buspirone Hcl | Buspirone Hcl | 140 | 18 |
| Carvedilol | Carvedilol | 138 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 135 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 126 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 125 | 33 |
| Pregabalin | Pregabalin | 122 | 26 |
| Linzess | Linaclotide | 120 | 22 |
| Montelukast Sodium | Montelukast Sodium | 118 | 23 |
| Divalproex Sodium | Divalproex Sodium | 106 | 12 |
| Spironolactone | Spironolactone | 106 | 19 |
| Metformin Hcl Er | Metformin Hcl | 104 | 27 |
| Levetiracetam | Levetiracetam | 102 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 20 |
| Entresto | Sacubitril/Valsartan | 89 | 13 |
| Ozempic | Semaglutide | 87 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 84 | 59 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 11 |
| Finasteride | Finasteride | 81 | 15 |
| Ondansetron Odt | Ondansetron | 80 | 43 |
| Simvastatin | Simvastatin | 79 | 20 |
| Nystatin | Nystatin | 76 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | suppressed |
| Tradjenta | Linagliptin | 75 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 74 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | 12 |
| Latanoprost | Latanoprost | 72 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 16 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Fenofibrate | Fenofibrate | 69 | 20 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 11 |
| Baclofen | Baclofen | 65 | suppressed |
| Clonazepam | Clonazepam | 64 | 13 |
| Olanzapine | Olanzapine | 64 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 32 |
| Ibuprofen | Ibuprofen | 60 | 12 |
| Lorazepam | Lorazepam | 60 | 13 |
| Novolog Flexpen | Insulin Aspart | 60 | suppressed |
| Sucralfate | Sucralfate | 60 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | suppressed |
| Gemtesa | Vibegron | 59 | suppressed |
| Prednisone | Prednisone | 58 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 55 | suppressed |
| Lovastatin | Lovastatin | 54 | suppressed |
| Eszopiclone | Eszopiclone | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 43 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 51 | 20 |
| Levalbuterol Hcl | Levalbuterol Hcl | 50 | suppressed |
| Temazepam | Temazepam | 49 | 14 |
| Atenolol | Atenolol | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Nifedipine Er | Nifedipine | 48 | 12 |
| Cephalexin | Cephalexin | 47 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Benazepril Hcl | Benazepril Hcl | 46 | 11 |
| Fluconazole | Fluconazole | 46 | 35 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 14 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 39 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 18 |
| Cefdinir | Cefdinir | 37 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | 22 |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 12 |
| Naproxen | Naproxen | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lactulose | Lactulose | 30 | 16 |
| Valsartan | Valsartan | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Verapamil Sr | Verapamil Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dupixent Syringe | Dupilumab | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,194.72 · 35 records | Janssen Pharmaceuticals, Inc | ABRYSVO, AUSTEDO XR, BREZTRI, CAPLYTA, COLLAGENASE SANTYL, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FUROSCIX, LEQVIO, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, SPRAVATO, Senza, VIBERZI, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error